Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference
Caladrius Biosciences (Nasdaq: CLBS) announced its participation in the H.C. Wainwright 22nd Annual Global Investment Conference, set for September 14-16, 2020. David J. Mazzo, Ph.D., President and CEO, will present on September 15 at 1:00 p.m. EDT. The company focuses on cellular therapies aimed at reversing diseases, with product candidates including CLBS119 for severe COVID-19 lung damage and several therapies for ischemic diseases. Their lead product, HONEDRA®, is under potential conditional approval in Japan for critical limb ischemia.
- None.
- None.
BASKING RIDGE, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020.
Presentation Details:
Date & Time: Tuesday, September 15th at 1:00 p.m. (EDT)
Presenter: David J. Mazzo, Ph.D., President and Chief Executive Officer
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.
The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.
Contact:
Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com
FAQ
When is Caladrius Biosciences participating in the H.C. Wainwright Conference?
Who is the presenter for Caladrius at the investment conference?
What time will Caladrius present at the H.C. Wainwright Conference?
What are the key product candidates of Caladrius Biosciences?
What is the significance of HONEDRA® in Caladrius' product pipeline?
